Glioblastoma—the most aggressive form of brain cancer—remains one of medicine's biggest challenges. Despite surgery, ...

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A 37% ...

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM) ...

Alecensa (alectinib) demonstrated a 22% reduction in the risk of death compared with Xalkori (crizotinib) in the frontline setting of patients with advanced ALK-positive non–small cell lung cancer ...

An analysis of secondary endpoints showed that GLP-1 agonist users had a significantly lower risk of myocardial or cerebral ...

Industry watchers who cheered on Summit Therapeutics’ claim that the first global phase 3 trial of its Akeso-partnered PD-1xVEGF drug showed consistent benefit between China and Western populations ...

In the dynamic field of oncology, the quest for precise biomarkers to predict cancer risk, prognosis, and treatment response is paramount. These insights directly inform personalized therapeutic ...

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...

Tissue yielding sufficient RNA and analyzable data for GES profiling analysis (Nanostring nCounter PanCancer IO360) was available from 27 patients, including 19 pretreatment samples. Baseline samples ...

“Dewpoint Therapeutics Announces an Open IND for First-in-Class Condensate Modulator DPTX3186 for Wnt-Driven Cancers,” by Dewpoint Therapeutics. News release; Oct. 21, 2025. For more news on cancer ...